MoneyDiscourse
← All companies

LLY

ELI LILLY & Co · Health Care

8 quarters · 57 figures · latest Q3 FY2026 filed 2026-10-29 →

Compared

6 of 8 · select any line below to add or remove it ·

  • Revenue

    $24.4bn+38.6% Y/Y

    Q3 FY2026

  • Net income

    $6.45bn+15.5% Y/Y

    Q3 FY2026

  • Earnings per share - diluted

    $7.22+16.3% Y/Y

    Q3 FY2026

  • Gross Margin - As Reported

    $20.46bn+40.2% Y/Y

    Q3 FY2026

  • Operating income

    $8.61bn+16.9% Y/Y

    Q3 FY2026

  • Acquired IPR&D

    $4.18bn+537.3% Y/Y

    Q3 FY2026

Reported figures

Click any line for its full history. Each figure links to the filing it was read from.

Income statement

26 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Acquired IPR&Dacquired_iprd
$529m$584m$2.78bn$4.18bn+537.3%+50.6%
Cost of salescost_of_sales
$3.37bn$3.58bn$3.27bn$3.93bn+30.8%+20.3%
Dividends paid per sharedividends_per_share
$1.50$1.73$1.73$1.73+15.3%+0.0%
Earnings per share - dilutedeps_diluted
$7.39$8.26$7.94$7.22+16.3%−9.1%
Earnings per share – Non-GAAPeps_diluted_non_gaap
$7.54$8.55$8.38$7.48+6.6%−10.7%
Gross Margin - As Reportedgross_margin
$15.92bn$16.22bn$19.71bn$20.46bn+40.2%+3.8%
Gross Margin - Non-GAAPgross_margin_non_gaap
$16.04bn$16.35bn$19.83bn$20.59bn+40.0%+3.8%
Income tax expenseincome_tax_expense
$1.63bn$1.45bn$2.15bn$1.96bn+18.5%−9.2%
Marketing, selling, and administrativemarketing_selling_administrative
$3.13bn$2.93bn$3.43bn$3.13bn+14.0%−8.9%
Net incomenet_income
$6.64bn$7.4bn$7.1bn$6.45bn+15.5%−9.1%
Net income – Non-GAAPnet_income_non_gaap
$6.77bn$7.66bn$7.49bn$6.68bn+5.8%−10.9%
Operating incomeoperating_income
$8.37bn$8.92bn$8.98bn$8.61bn+16.9%−4.1%
Research and developmentresearch_and_development
$3.8bn$3.51bn$3.82bn$4.25bn+22.5%+11.2%
Revenuetotal_revenue
$19.29bn$19.8bn$22.97bn$24.4bn+38.6%+6.2%
Income before income taxesincome_before_income_taxes
—$8.85bn$9.25bn$8.41bn+16.2%−9.1%
Other income (expense)other_income_expense
—−$65m$269m−$202m−53.0%−175.1%
Asset impairment, restructuring and other special chargesasset_impairment_restructuring_special_charges
—$279m$703m$303m−17.0%−56.9%
Acquired IPR&Dacquired_iprd_per_share
—$0.52—$4.57+543.7%—
Net interest income (expense)net_interest_income_expense
——−$274m−$316m−177.2%−15.3%
Asset impairment, restructuring and other special chargesasset_impairment_restructuring
$84m———−75.6%—
Weighted-average shares outstanding (thousand) - diluteddiluted_shares
898,002———−0.6%—
Weighted-average shares outstanding (thousand) - diluteddiluted_shares_outstanding
———893,439−0.6%—
Weighted-average shares outstanding (thousand) - diluteddiluted_shares_outstanding_thousands
——893,671—−0.7%—
Weighted-average shares outstanding (thousand) - diluteddiluted_shares_thousands
—895,918——−0.5%—
Income before income taxesincome_before_taxes
$8.27bn———+64.0%—
Net other income (expense)net_other_income_expense
——$543m—+356.3%—

Segments

17 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Mounjaromounjaro_revenue
$7.41bn$8.66bn—$10.72bn+64.6%—
Zepboundzepbound_revenue
$4.26bn$4.16bn—$5.35bn+49.2%—
Ebglyssebglyss_revenue
—$145m—$202m+59.1%—
Jaypircajaypirca_revenue
—$165m—$228m+59.4%—
Kisunlakisunla_revenue
—$124m—$193m+175.7%—
Omvohomvoh_revenue
—$80m—$114m+75.4%—
Inluriyoinluriyo_revenue
—$35m—$73m——
Ebglyssrevenue_ebglyss
——$201m—+131.0%—
Jaypircarevenue_jaypirca
——$192m—+56.1%—
Kisunlarevenue_kisunla
——$167m—+240.8%—
Mounjarorevenue_mounjaro
——$9.94bn—+91.2%—
Omvohrevenue_omvoh
——$102m—+36.0%—
Zepboundrevenue_zepbound
——$4.93bn—+45.8%—
Verzenioverzenio_revenue
$1.6bn———+3.2%—
Foundayofoundayo_revenue————$184m——
Foundayorevenue_foundayo———$98m———
Inluriyorevenue_inluriyo———$75m———

Operating

10 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Key Products revenuekey_products_revenue
—$13.4bn$15.7bn$17.1bn—+8.9%
Jardiance sales-based milestonesjardiance_sales_based_milestones
———$410m+105.0%—
Revenue outside the U.S.outside_us_revenue
—$7.7bn—$9.3bn——
Revenue in the U.S.us_revenue
—$12.1bn—$15.1bn——
Mounjaro revenue outside the U.S.mounjaro_outside_us_revenue————$5.7bn——
Mounjaro U.S. revenuemounjaro_us_revenue————$5bn——
Mounjaro revenue outside the U.S.revenue_mounjaro_outside_us———$5.2bn———
Mounjaro U.S. revenuerevenue_mounjaro_us———$4.8bn———
Revenue outside the U.S.revenue_outside_us———$8.6bn———
Revenue in the U.S.revenue_us———$14.4bn———

Margins

4 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Effective tax rate - Reportedeffective_tax_rate
19.7%16.4%23.3%23.3%+2.2%+0.0%
Effective tax rate - Non-GAAPeffective_tax_rate_non_gaap
19.7%16.5%22.2%24.0%+35.6%+8.1%
Gross Margin as a percent of revenue - As Reportedgross_margin_pct
82.5%81.9%85.8%83.9%+1.2%−2.2%
Gross Margin as a percent of revenue - Non-GAAPgross_margin_pct_non_gaap
83.2%82.6%86.3%84.4%+1.0%−2.2%

Guided vs delivered

What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.

Data from company filings. Not investment advice.